Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
A health ministry panel has agreed to continue treating Category A medicines as products that should be handled separately from bundled price negotiations under Japan’s commercial guidelines for ethical drugs, even after the redefinition of “stable supply medicines” later this…
To read the full story
Related Article
- Japan's Revised Drug Distribution Guidelines Take Effect
March 6, 2026
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
REGULATORY
- MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
- MHLW Seeks 13.9 Billion Yen to Boost Domestic Biosimilar Production
September 2, 2026
- Health Minister Mum on Legislation for Chuikyo Reform
September 2, 2026
- Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…